Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BM-MSCL is a stable human bone marrow-derived mesenchymal stem cell line. It was generated by infecting primary human bone marrow mesenchymal stem cells (BM-MSCs) with a retroviral SV40 vector to enable extensive expansion while maintaining a stable phenotype. Characterized by cell surface markers such as CD54, CD90, CD105, CD166, and CD49e, BM-MSCL was utilized in a rodent model of meniscal injury and post-traumatic osteoarthritis as a control. In this study, intra-articular injections of BM-MSCL did not demonstrate significant improvements in meniscus tear healing or reduction of cartilage degradation compared to saline-treated control animals. Furthermore, BM-MSCL exhibited higher expression of catabolic enzymes like MMP2, MMP13, and ADAMTS4 when compared to cartilage-derived progenitor cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BM-MSCL.